Tonix publishes Phase 1 results showing TNX-1500 blocked immune responses at all doses

Filed May 27, 2026 · Period ending May 27, 2026 · ~1 min read

Key Changes

• high

  TNX-1500 successfully blocked primary immune responses at all three tested doses (3, 10, and 30 mg/kg) in 26 healthy volunteers, with higher doses also blocking secondary responses and the lowest dose reducing them by 70%.

  Item 8.01 verify on EDGAR →
• high

  Peer-reviewed publication in Journal of Clinical Immunology validates first-in-human Phase 1 trial data for TNX-1500, an antibody being developed to prevent organ transplant rejection and treat autoimmune diseases.

  Item 8.01 verify on EDGAR →
• medium

  The randomized, double-blind, placebo-controlled study used single-ascending doses and monitored participants for 120 days, evaluating safety, tolerability, pharmacokinetics, and immune response suppression.

  Item 8.01 verify on EDGAR →